NASDAQ$NOVT
Novanta Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year 2019.
Novanta's Q4 2019 revenue was stronger than expected, with the medical business growing at a double-digit pace and new product revenue reaching record levels, despite challenges in industrial capital spending markets.
- GAAP revenue was $159.7 million, a 2.3% increase year-over-year.
- GAAP operating income was $13.0 million, compared to $15.7 million in Q4 2018.
- Adjusted EBITDA was $30.5 million, compared to $30.8 million in Q4 2018.
- Operating cash flow was $35.4 million, compared to $21.9 million in Q4 2018.
Headline financials
Revenue & EPS history
Novanta · Revenue · Quarterly
$160M
Revenue by segment
Novanta · $83.4M total across 1 segment · Q3 2023
- Medical Solutions$83.4M—100.0%
Forward guidance
For the first quarter of 2020, the Company expects GAAP revenue of approximately $144 million to $154 million. We estimate that the effects of COVID-19 on our revenue in the first quarter will be approximately $10 million to $15 million. The Company expects Adjusted EBITDA to be in the range of $23 million to $26 million and Adjusted Diluted EPS to be in the range of $0.34 to $0.42.
Tailwinds
- Momentum around new products introductions and design win activities.
- Strong medical end market demand for our products.
- Expects Adjusted EBITDA to be in the range of $23 million to $26 million.
- Expects Adjusted Diluted EPS to be in the range of $0.34 to $0.42.
- Believes this disruption is only temporary and that overall, we remain fundamentally strong and well positioned for growth and success.
Headwinds
- Expecting short-term disruptions to our business in the first quarter due to the public health epidemic originating in China.
- Epidemic is expected to have a temporary impact on our sales of products sold directly into China.
- Epidemic is expected to have a temporary impact on our supply of products sourced from China to feed our global factories.
- Epidemic is expected to have a temporary impact on our demand from our non-China-based customers due to their dependencies on the Chinese market.
- The effects of the COVID-19 outbreak represent our view as of today, based on our current expectations regarding the timing of business resumption in our operations, customers, and our Chinese supply chain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
+2.3%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.4%
Avg return
30 days after
64%
41 / 64 earnings
Positive
+22.9%
Q3 2018
Best reaction
-11.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +10.5% | — | |
| Q4 2025 | -2.2% | -7.9% | -19.4% | |
| Q3 2025 | +8.4% | -17.0% | -10.0% | |
| Q1 2025 | -1.7% | +2.4% | +5.3% | |
| Q4 2024 | +7.2% | +4.6% | -4.2% | |
| Q3 2024 | +4.5% | +4.9% | -4.5% | |
| Q2 2024 | +7.6% | +9.4% | +10.3% | |
| Q1 2024 | -1.6% | +0.1% | +0.8% | |
| Q4 2023 | +9.9% | +12.1% | +11.1% | |
| Q3 2023 | -11.0% | -11.0% | +9.4% | |
| Q2 2023 | -11.3% | -11.2% | -6.9% | |
| Q1 2023 | +2.2% | +0.5% | +4.8% | |
| Q4 2022 | -6.1% | -3.7% | +1.4% | |
| Q3 2022 | -3.5% | +10.5% | +7.2% | |
| Q2 2022 | -0.4% | -0.5% | -13.6% | |
| Q1 2022 | +3.1% | +9.5% | +3.9% | |
| Q4 2021 | -1.0% | -2.0% | +4.1% | |
| Q3 2021 | -7.4% | -8.2% | -5.7% | |
| Q2 2021 | +5.1% | +3.8% | +8.9% | |
| Q1 2021 | +2.5% | +7.0% | +8.1% | |
| Q4 2020 | -1.3% | -4.1% | -0.3% | |
| Q3 2020 | -2.3% | -7.5% | -2.3% | |
| Q2 2020 | +4.8% | +3.4% | -6.1% | |
| Q1 2020 | +6.6% | +3.8% | +14.2% | |
| Q4 2019 | +5.6% | +8.4% | -10.0% | |
| Q3 2019 | -5.9% | -8.3% | -0.1% | |
| Q2 2019 | -5.3% | -8.4% | +2.0% | |
| Q1 2019 | -5.8% | -5.3% | -6.9% | |
| Q4 2018 | +4.7% | +4.6% | +8.6% | |
| Q3 2018 | +22.9% | +21.7% | -1.9% | |
| Q2 2018 | -0.6% | +1.9% | +13.2% | |
| Q1 2018 | +2.8% | +3.9% | +8.1% | |
| Q4 2017 | +2.8% | +0.9% | -4.1% | |
| Q3 2017 | +10.1% | +10.1% | -1.5% | |
| Q2 2017 | -0.8% | +1.9% | +4.0% | |
| Q1 2017 | +8.6% | +12.0% | +34.0% | |
| Q4 2016 | +0.2% | +3.9% | +5.5% | |
| Q3 2016 | -1.2% | +1.5% | +16.9% | |
| Q2 2016 | +1.7% | +2.9% | +7.9% | |
| Q1 2016 | -0.6% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +2.7% | — | — | |
| Q2 2015 | +1.1% | — | — | |
| Q1 2015 | +0.2% | — | — | |
| Q4 2014 | +1.1% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q2 2014 | +4.1% | — | — | |
| Q1 2014 | +1.3% | — | — | |
| Q4 2013 | +2.3% | — | — | |
| Q3 2013 | +9.9% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2009 | -1.5% | — | — | |
| Q4 2012 | -1.5% | — | — | |
| Q3 2012 | +0.4% | — | — | |
| Q2 2012 | -8.6% | — | — | |
| Q1 2011 | +10.8% | — | — | |
| Q1 2012 | +2.6% | — | — | |
| Q4 2011 | +0.3% | — | — | |
| Q3 2010 | +6.0% | — | — | |
| Q3 2011 | +6.0% | — | — | |
| Q4 2010 | +18.8% | — | — | |
| Q2 2011 | +18.8% | — | — | |
| Q2 2010 | +18.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro